Liminatus Pharma, Inc. (LIMN) Stock Price & How to Invest

Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company based in Cerritos, California, focused on therapies that use the immune system to detect and attack cancer cells. Its lead candidate is IBA101, a humanized anti-CD47 monoclonal antibody intended as a next-generation immune checkpoint inhibitor, with an initial focus on advanced solid tumors including non-small cell lung cancer. The broader pipeline includes a Guanylyl Cyclase C (GCC) cancer vaccine program and, through a planned merger with InnocsAI, CAR-T and antibody candidates such as IBC101, a CD19xCD22 bivalent CAR-T cleared for an early-phase study in Korea. The company has no approved products and generates no revenue.

Liminatus became a public company by merging with the special purpose acquisition company Iris Acquisition Corp and began trading on Nasdaq under the ticker LIMN on May 1, 2024. Since then it has operated under significant financial strain. For 2025 it reported zero revenue and a net loss of roughly $10.2 million, ending the year with only about $338,000 in cash and an accumulated deficit near $38.9 million, prompting management to disclose substantial doubt about its ability to continue as a going concern. A February 2026 equity and warrant financing raised roughly $3.4 million in net proceeds, lifting cash to about $1.9 million by the end of the first quarter of 2026, when the accumulated deficit reached about $40.0 million. The company received multiple Nasdaq deficiency notices over minimum bid price and market value requirements during late 2025 and 2026, and in May 2026 it received a delisting determination, which it appealed to a Nasdaq Hearings Panel, automatically staying any suspension while the appeal is pending.

Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. It has no products and no revenue, an accumulated deficit near $40 million, and management has disclosed substantial doubt about its ability to continue as a going concern, meaning it may be unable to fund operations without raising more capital on potentially harsh terms. Its lead asset, IBA101, is still early and unproven, and CD47 is a target where larger, better-funded programs have repeatedly failed, so a single clinical setback could be decisive given how concentrated the value is in a handful of early programs. The company faces an active Nasdaq delisting process, and continued financings, plus the share issuance tied to the proposed InnocsAI merger, point to heavy dilution. The stock trades as a sub-dollar micro-cap with low liquidity and high volatility, and a total loss is a realistic outcome.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Liminatus Pharma, Inc.'s investor relations page or your broker.

• Revenue: $0 (no approved products)
• Net loss (FY2025): ~$10.2 million
• Net loss (Q1 2026): ~$1.1 million
• Cash: ~$1.9 million (Mar 31, 2026)
• Accumulated deficit: ~$40.0 million
• Market cap: ~$5-6 million (mid-2026, sub-$1 share)

For a clinical-stage biotech with no revenue, traditional metrics like P/E or price-to-sales do not apply, so the numbers that matter are cash on hand, the quarterly cash burn, and the runway between them. Here the runway is very short: a roughly $1 million quarterly loss against under $2 million in cash means the company must keep raising money to operate, which is why management disclosed going concern doubt. Read the market cap as the market's small, heavily discounted estimate of a binary pipeline rather than a multiple of any earnings, and treat each financing and clinical update as the real value driver.

There are three common ways to get LIMN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so LIMN sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where LIMN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Liminatus Pharma is a distressed, pre-revenue micro-cap biotech whose value depends almost entirely on future clinical milestones it has not yet reached, with no products, no revenue, and ongoing going concern and delisting risk. In a portfolio it behaves like a binary option on its early-stage pipeline, capable of large percentage swings on financing and trial news while carrying a real chance of going to zero.

Whether LIMN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LIMN a buy?, and where the stock could go from here in the LIMN stock forecast.

For income investors, whether LIMN pays a dividend and how the payout looks is covered in does LIMN pay a dividend?